- Home
- RNAC vs ELDN Comparison
RNAC vs ELDN Comparison
Compare RNAC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAC | ELDN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.1M | 208.6M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RNAC | ELDN |
|---|---|---|
| Price | $7.79 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $38.80 | $8.50 |
| AVG Volume (30 Days) | 117.8K | ★ 680.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,913,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 49.64 | N/A |
| 52 Week Low | $5.98 | $1.35 |
| 52 Week High | $18.80 | $4.60 |
Technical Indicators
Market Signals| Indicator | RNAC | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 64.00 |
| Support Level | $6.20 | $2.48 |
| Resistance Level | $7.99 | $2.77 |
| Average True Range (ATR) | 0.62 | 0.16 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 74.89 | 78.62 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.